Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP's New Sonolith i-move Lithotripter Receives Best 2010 Product Innovation Award
LYON, France , Nov. 23, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes .
View HTML
Toggle Summary EDAP Reports Third Quarter 2010 Financial Results
Third Quarter Highlights   Revenues increased 15.5% year-over-year to EUR 5.3 million ( USD 7.0 million ) Gross margin rose 500 basis points over last year to 41.6% Operating loss, excluding lower FDA clinical trial expense, improved by EUR 576,000 to EUR 404,000 Net loss improved by EUR 3.9
View HTML
Toggle Summary EDAP to Collaborate on Use of HIFU in Cancer Drug Delivery Following Successful Feasibility Study
Agreement With Epitarget AS and INSERM
View HTML
Toggle Summary EDAP Schedules Webcast and Conference Call for Third Quarter 2010 Results
LYON, France, Oct 27, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the details relating to its third quarter 2010 results announcement, which will take place on Wednesday, November 17, 2010, before the
View HTML
Toggle Summary EDAP Successfully Completes Preliminary Trial of HIFU in Liver Cancer
Plan for Second, Larger Trial
View HTML
Toggle Summary EDAP Expands Japan Sales Force
Oct 7, 2010 (GlobeNewswire via COMTEX News Network) -- Focus on World's Largest Lithotripsy Market Installs First Sonolith i-sys in Japan LYON, France, Oct. 7, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has strengthened
View HTML
Toggle Summary EDAP to Present at Rodman & Renshaw Annual Global Investment Conference
LYON, France, Sep 9, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski, Chief Executive Officer, and Eric Soyer, Chief Financial Officer, are scheduled to present at the Rodman & Renshaw
View HTML
Toggle Summary EDAP Reports Publication of Long-Term Clinical Results for Largest Cohort of Ablatherm-HIFU Patients
Favorable Clinical Outcomes for Prostate Cancer Patients Treated Over 15 Years
View HTML
Toggle Summary EDAP Media Interview Highlights Prostate Cancer
Ablatherm-HIFU Optimally Positioned for Focal Therapy
View HTML
Toggle Summary EDAP Heightens Participation in Global Urology Congresses
Supports Strategic Marketing Initiatives by Strong Presence at Major Events
View HTML